AndreaBozzo/ceres-open-data-index huggingface dataset:
Child Maltreatment 2012 – Data Tables

The Children's Bureau has provided eight data tables in Excel format as an aid to researchers and others who would like to use the data from the Child Maltreatment 2012 report. The provided tables contain basic counts and demographic information that the Children's Bureau believes are of special interest to researchers. These materials are in the public domain and may be reproduced fully or partially without permission of the federal government. The courtesy of attribution is requested. Please note that these tables are a source for the Child Maltreatment 2012 report and if used in research the table name should be changed and we request that source of the data be noted. The recommended citation is provided below:

U.S. Department of Health and Human Services, Administration for Children and Families, Administration on Children, Youth and Families, Children’s Bureau.(2012). Child maltreatment 2012. Available from /programs/cb/research-data-technology/statisti....

Metadata-only record linking to the original dataset. Open original dataset below.
Age of Substance Use Initiation among Treatment Admissions Aged 18 to 30

This is a Treatment Episode Data Set (TEDS) short report showing the age of substance use initiation among treatment admissions aged 18 to 30 in 2011. The Treatment Episode Data Set (TEDS) is a national data system of annual admissions to substance abuse treatment facilities. TEDS received treatment admission records from 46 states, the District of Columbia, and Puerto Rico in 2011.
Compound 528010: 3-Butenyl 4-nitrobenzoate

Chemical compound data from PubChem database. IUPAC Name: but-3-enyl 4-nitrobenzoate. Molecular Formula: C11H11NO4. Molecular Weight: 221.21. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Risk factors for hepatitis C virus infection among blood donors in southern Brazil: a case-control study

Background
          In Brazil, it is estimated that between 2.5 and 4.9% of the general population present anti-hepatitis C virus (HCV) antibodies, which corresponds to as many as 3.9 to 7.6 million chronic carriers. Chronic liver disease is associated with HCV infection in 20% to 58% of the Brazilian patients. The objective of this case-control study was to investigate the risk factors for presence of anti-HCV antibody in blood donors in southern Brazil.
        
        
          Methods
          One hundred and seventy eight blood donors with two positive ELISA results for anti-HCV were cases, and 356 controls tested negative. A standardized questionnaire was used to collect data concerning demographic and socioeconomic aspects, history of previous hepatitis infection, social and sexual behaviors, and number of donations. Variables were grouped into sets of hierarchical categories. Cases and controls were compared using logistic regression, odds ratios, and 95% confidence intervals. The statistical significance of the associations was assessed through likelihood ratio tests based on a P value < 0.05.
        
        
          Results
          The prevalence of anti-HCV among blood donors was 1.1%. Most of the donors were white and males. In the multivariate analysis, independent predictors of anti-HCV positivity were: intravenous drug use, blood transfusion >10 years earlier, having had two to four sexually transmitted diseases, incarceration, tattooing, sex with a hepatitis B or C virus carrier or with intravenous drug users.
        
        
          Conclusion
          Intravenous drug use, blood transfusion, and tattooing were the main risk factors for anti-HCV positivity among blood donors from southern Brazil, but sexual HCV transmission should also be considered.
2010 State Profile — Delaware

This state profile includes data from facilities in Delaware that reported to N-SSATS for the survey reference date March 31, 2010. Data were collected on the location, characteristics, services offered, and number of clients in treatment at alcohol and drug abuse treatment facilities (both public and private) in Delaware. In Delaware, 37 substance abuse treatment facilities were included in the 2010 N-SSATS, reporting that there were 4,981 clients in substance abuse treatment on March 31, 2010. The survey response rate in Delaware was 94.9%.
Respiratory Syncytial Virus Laboratory Data (NREVSS)

Approximately 600 public health and clinical laboratories located throughout the United States, participate in surveillance for respiratory syncytial virus (RSV) through CDC's National Respiratory and Enteric Virus Surveillance System (NREVSS). The dataset contains a weekly summary of the total RSV tests and RSV detections reported to NREVSS. These data are reported on a voluntary basis. Clinical laboratories do not report demographic data through NREVSS. Testing practices and the number of participating laboratories may change from year to year. Results can be changed two years after the initial reporting week. However, discrepancies may be noted and updated at the discretion of the data stewards and key stakeholders.

Data are collected from collaborating university and community hospital laboratories, select states and county public health laboratories, and commercial laboratories. This information is submitted and updated on a weekly basis. 

While NREVSS strives to present the most precise national, regional and state respiratory viral trends with the least amount of burden possible for participating laboratories, there are a number of inherent limitations to this surveillance system. 

NREVSS does not collect patient-data or demographic information. Multiple samples may be collected from a single patient, so NREVSS results do not necessarily reflect the number of patients tested nor does it reflect hospitalizations or deaths related to a particular virus. 

Participating laboratories vary in size, testing capabilities, and areas served. Some institutions may receive and test samples from sites across a given state or even from multiple states. Without direct knowledge of the population base, NREVSS cannot be used to determine the prevalence or incidence of infection.


For more information on RSV surveillance and research please visit: https://www.cdc.gov/surveillance/nrevss and https://www.cdc.gov/rsv/research/us-surveillance.html
Patent AT-E399564-T1: [Translated] TREATMENT OF RHEUMATOID ARTHRITIS WITH ANTIBODIES TO IFN GAMMA

The present disclosure concerns the treatment of a patient with autoimmune disease, including AIDS, by neutralizing, removing or inhibiting different types of interferons, tumor necrosis factor, HLA class II antigens, IgE, and other pathological factors and/or their receptors, as well as neutralizing, removing or inhibiting autoantibodies, including antibodies to target cells, CD4 cells and DNA. Treatment comprises administration of an autoimmune inhibitor, or extracorporeal exposure of the patient's fluid to an immunosorbent comprising an autoimmune inhibitor, followed by return of the treated fluid to the patient; or it comprises a combined therapy involving extracorporeal immunosorption in conjunction with the administration of an autoimmune inhibitor.
Patent AT-E401756-T1: [Translated] CELLULAR ACCESS NETWORKS

In a mobile access network using packet transmission such as a UMTS (Universal Mobile Telephone System), a mobile station MS has a plurality of active soft handover connections (macrodiversity) to the network, each having a separate path from the mobile to a splitting/recombination node (RNC). Each path consists of a radio channel to a base station and a transport channel from the base station to the RNC. The quality of each radio channel is measured at the base station and a higher priority is given to connections having higher quality radio channels. Packets are marked according to the priority assigned to the channel via which they travel. Buffer management is effected in all nodes through which the packets travel to ensure that a lower packet loss ratio is experienced by higher priority packets.
Compound 526155: Dibutyl 3-chloro-phenyl phosphate

Chemical compound data from PubChem database. IUPAC Name: dibutyl (3-chlorophenyl) phosphate. Molecular Formula: C14H22ClO4P. Molecular Weight: 320.75. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
NNDSS - TABLE 1C. Arboviral diseases, St. Louis encephalitis virus to Western equine encephalitis virus

NNDSS - Table 1C. Arboviral diseases, neuroinvasive and non-neuroinvasive,  St. Louis encephalitis virus disease to Western equine encephalitis virus disease - 2019. In this Table, provisional cases* of notifiable diseases are displayed for United States, U.S. territories, and Non-U.S. residents. 

Note: 
This table contains provisional cases of national notifiable diseases from the National Notifiable Diseases Surveillance System (NNDSS). NNDSS data from the 50 states, New York City, the District of Columbia and the U.S. territories are collated and published weekly on the NNDSS Data and Statistics web page (https://wwwn.cdc.gov/nndss/data-and-statistics.html). Cases reported by state health departments to CDC for weekly publication are provisional because of the time needed to complete case follow-up. Therefore, numbers presented in later weeks may reflect changes made to these counts as additional information becomes available. The national surveillance case definitions used to define a case are available on the NNDSS web site at https://wwwn.cdc.gov/nndss/. Information about the weekly provisional data and guides to interpreting data are available at: https://wwwn.cdc.gov/nndss/infectious-tables.html. 

Footnotes: 
U: Unavailable — The reporting jurisdiction was unable to send the data to CDC or CDC was unable to process the data.
-: No reported cases — The reporting jurisdiction did not submit any cases to CDC.
N: Not reportable — The disease or condition was not reportable by law, statute, or regulation in the reporting jurisdiction.
NN: Not nationally notifiable — This condition was not designated as being nationally notifiable.
NP: Nationally notifiable but not published — CDC does not have data because of changes in how conditions are categorized.
Cum: Cumulative year-to-date counts.
Max: Maximum — Maximum case count during the previous 52 weeks.
* Case counts for reporting years 2018 and 2019 are provisional and subject to change. Cases are assigned to the reporting jurisdiction submitting the case to NNDSS, if the case's country of usual residence is the US, a US territory, unknown, or null (i.e. country not reported); otherwise, the case is assigned to the 'Non-US Residents' category. For further information on interpretation of these data, see https://wwwn.cdc.gov/nndss/document/Users_guide_WONDER_tables_cleared_final.pdf. 
† Previous 52 week maximum and cumulative YTD are determined from periods of time when the condition was reportable in the jurisdiction (i.e., may be less than 52 weeks of data or incomplete YTD data).
Compound 526539: 8-Hydroxy-5,7,8-trimethyl-2,10-dioxa-15-azatricyclo[10.5.1.015,18]octadec-4-ene-3,9-dione

Chemical compound data from PubChem database. IUPAC Name: 8-hydroxy-5,7,8-trimethyl-2,10-dioxa-15-azatricyclo[10.5.1.015,18]octadec-4-ene-3,9-dione. Molecular Formula: C18H27NO5. Molecular Weight: 337.4. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Distinct gene expression profiles of human type 1 and type 2 T helper cells

Background
          The development and activation of CD4+ helper T cell (Th) subsets with distinct patterns of unbalanced production of cytokines play an important part in infectious, allergic and autoimmune diseases. Human neonatal cord blood CD4+ Th cells can be polarized into type 1 or type 2-like effector cells in vitro by culturing them in the presence of interleukin (IL)-12 or IL-4, respectively. We have exploited this experimental system to identify marker genes that are differentially expressed by polarized Th1 and Th2 cells. An oligonucleotide microarray specifically designed to screen for inflammation-related candidate genes was used and the differential expression was further validated with a quantitative real-time RT-PCR method.
        
        
          Results
          In addition to the previously described marker genes of Th cells, we report subtle changes in the expression of several other genes that represent growth factors, receptors and other signaling molecules in polarized Th1 and Th2 cell subsets. Additionally, we describe a novel set of genes as Th1/Th2 differentiation markers for cells activated by anti-CD3 and anti-CD28 antibodies.
        
        
          Conclusions
          This study demonstrates the power of the targeted use of microarrays in combination with quantitative real-time RT-PCR in identifying and validating new marker genes for gene expression studies.
Compound 527792: But-3-enyl 3-chlorobenzoate

Chemical compound data from PubChem database. IUPAC Name: but-3-enyl 3-chlorobenzoate. Molecular Formula: C11H11ClO2. Molecular Weight: 210.65. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Managed Care Institutional Provider Network Data: June 30, 2016

The primary purpose for the Provider Network Data System is to collect data needed to evaluate the provider networks including physicians, hospitals, labs, home health agencies, durable medical equipment providers, etc., for all types of Managed Care plans in New York State, including HIV Special Need Plans (SNP), Family Health Plus (FHP) Buy-In, Programs of All-Inclusive Care for the Elderly (PACE), and Non-PACE Managed Long-Term Care (MLTC) plans. This dataset reflects institutional provider data. Provider Network Data System information is self reported. For more information, go to http://www.health.ny.gov/health_care/managed_care/.
Compound 528905: Hydroxymethyl-methaqualon

Chemical compound data from PubChem database. IUPAC Name: 2-(hydroxymethyl)-3-(2-methylphenyl)quinazolin-4-one. Molecular Formula: C16H14N2O2. Molecular Weight: 266.29. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
National Directory of Drug and Alcohol Abuse Treatment Facilities - 1991

The National Directory of Drug and Alcohol Abuse Treatment Programs 1991 lists federal, state, local, and private facilities that provide substance abuse treatment services. The directory includes treatment facilities that are licensed, certified, or otherwise approved for inclusion in the directory by their state substance abuse agencies and that responded to the 1990 National Survey of Substance Abuse Treatment Services (N-SSATS). The information about each facility that appears in this directory was provided by that facility in response to the 1990 N-SSATS. The Substance Abuse and Mental Health Services Administration (SAMHSA) conducts the N-SSATS annually.
Patent AT-E400320-T1: [Translated] HAIR CARE COMPOSITION WITH WAX EFFECT IN THE FORM OF AN AEROSOL

A cosmetic composition for the hair, packaged in an aerosol device, comprises 5-10 wt.% of an anionic fixing polymer, 15 wt.% or more of polyol(s) of molecular weight below 500, a hydroalcoholic or aqueous medium containing at least 10 wt.% of water with respect to the composition, and 30 wt.% or more of one or more propellant gases.  An Independent claim is included for a cosmetic procedure comprising the application to the hair of the composition.
Compound 528227: 1-Oxa-4,7,10-trithiacyclododecane

Chemical compound data from PubChem database. IUPAC Name: 1-oxa-4,7,10-trithiacyclododecane. Molecular Formula: C8H16OS3. Molecular Weight: 224.4. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Child Welfare Training

This program upgrades the skills, knowledge and qualifications of prospective and current child welfare agency staff and supports special projects for training personnel to work in the field of child welfare. These discretionary grants are awarded to public and private non-profit institutions of higher learning and are designed to assist State child welfare agencies in developing a stable and highly skilled workforce for providing effective child welfare services. Further, the Child Welfare Discretionary Grant Projects develop and maintain a strong University- Public Agency Partnership toward the goal of identifying and developing the appropriate staff competencies.

Metadata-only record linking to the original dataset. Open original dataset below.
Definition of “Short-Term Support” under the Temporary Pandemic  Flexibilities of Division X for Title IV-E Agencies Participating in the Title IV-E  Kinship Navigator Program

This Program Instruction (PI) provides clarifying guidance to title IV-E agencies on the parameters of short-term support that may be provided to kinship families with title IV-E kinship navigator funding under the flexibilities of Section 8, Division X of P.L. 116-260.

Metadata-only record linking to the original dataset. Open original dataset below.
Patent AT-E401332-T1: [Translated] NEW POLYMORPHS OF OLNZAPINE HYDROCHLORIDE

The present invention relates to new crystalline forms I, II and III of 2-methyl-4-(4-methylpiperazin-1-yl)-10H-thieno[2,3-b][1,5]-benzodiazepine hydrochloride, a process for the preparation thereof and pharmaceutical compositions containing the same. Said new polymorphic forms are useful as active ingredients for the treatment of psychotic conditions.
What is the optimal prophylaxis for treatment of cardiac allograft vasculopathy?

Coronary artery disease in the transplanted heart, also known as cardiac allograft vasculopathy (CAV), is one of the major causes of mortality late after transplantation. It affects up to 50% of all heart transplant recipients within 5 years of surgery. The mechanisms of CAV are multifactorial and include both immune and nonimmune factors. Ischemia of the graft at the time of transplantation is one of the more important nonimmune factors, because this leads to endothelial cell injury. Immune factors involving cellular and humoral rejection can further insult the vascular endothelial cell, leading to a cascade of immunologic responses. The optimal treatment prophylaxis for CAV has not been established. The treatment approach to this major post-transplant complication includes modification of risk factors through medical therapies and strategies. The early use of diltiazem and/or pravastatin or simvastatin has been demonstrated to be effective in reducing the development of CAV, but does not completely prevent it. There are many ongoing studies involving newer immunosuppressive agents that may hold promise for the future.
Public Health Statistics - Life Expectancy By Race Ethnicity - Historical

Note: This dataset is historical only and there are not corresponding datasets for more recent time periods. For that more-recent information, please visit the Chicago Health Atlas at https://chicagohealthatlas.org.

This dataset gives the average life expectancy and corresponding confidence intervals for sex and racial-ethnic groups in Chicago for the years 1990, 2000 and 2010.  See the full description at: 
https://data.cityofchicago.org/api/views/3qdj-cqb8/files/pJ3PVVyubnsS2SpGO5P5IOPtNgCJZTE3LNOeLagC3mw?download=true&filename=P:\EPI\OEPHI\MATERIALS\REFERENCES\Life Expectancy\Dataset description_LE_ Sex_Race_Ethnicity.pdf
Compound 526389: 1,9-Dibromo,2,3-dichloro-dibenzo-dioxin

Chemical compound data from PubChem database. IUPAC Name: 1,9-dibromo-2,3-dichlorodibenzo-p-dioxin. Molecular Formula: C12H4Br2Cl2O2. Molecular Weight: 410.9. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
NLM LitArch Open Access Subset

A subset of the total collection of books and documents in the NLM Literature Archive (NLM LitArch), accessible through the Bookshelf website, are available through the NLM LitArch Open Access subset. Contents in the NLM LitArch Open Access subset generally include works which are in the public domain, works which are available under a Creative Commons or similar license, and works whose authors or publishers have explicitly agreed to the terms of the NLM LitArch Open Access subset. Except for public domain works, works in the NLM LitArch Open Access subset are still protected by copyright, but are made available under a Creative Commons or similar license that generally allows more liberal redistribution and reuse than a traditional copyrighted work. The license terms are not the same for each work. Read the license text which is available with each downloadable file to determine terms of use.
Compound 530786: 4-Cyanobenzoic acid, 2-isopropoxyphenyl ester

Chemical compound data from PubChem database. IUPAC Name: (2-propan-2-yloxyphenyl) 4-cyanobenzoate. Molecular Formula: C17H15NO3. Molecular Weight: 281.3. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
2015 CMHS Uniform Reporting System (URS) Table for California

2015 Center for Mental Health Services (CMHS) Uniform Reporting System (URS) Output Tables for California. The URS state reporting system is collected annually to support the Community Mental Health Services Block Grant program. State Mental Health Authorities report on National Outcome Measures (NOMS), evidence based practices, and utilization measures providing an overview of state mental health delivery systems.
The CXC chemokine cCAF stimulates precocious deposition of ECM molecules by wound fibroblasts, accelerating development of granulation tissue

Background
          During wound repair, fibroblasts orchestrate replacement of the provisional matrix formed during clotting with tenascin, cellular fibronectin and collagen III. These, in turn, are critical for migration of endothelial cells, keratinocytes and additional fibroblasts into the wound site. Fibroblasts are also important in the deposition of collagen I during scar formation. The CXC chemokine chicken Chemotactic and Angiogenic Factor (cCAF), is highly expressed by fibroblasts after wounding and during development of the granulation tissue, especially in areas where extracellular matrix (ECM) is abundant. We hypothesized that cCAF stimulates fibroblasts to produce these matrix molecules.
        
        
          Results
          Here we show that this chemokine can stimulate precocious deposition of tenascin, fibronectin and collagen I, but not collagen III. Studies in culture and in vivo show that tenascin stimulation can also be achieved by the N-terminal 15 aas of the protein and occurs at the level of gene expression. In contrast, stimulation of fibronectin and collagen I both require the entire molecule and do not involve changes in gene expression. Fibronectin accumulation appears to be linked to tenascin production, and collagen I to decreased MMP-1 levels. In addition, cCAF is chemotactic for fibroblasts and accelerates their migration.
        
        
          Conclusions
          These previously unknown functions for chemokines suggest that cCAF, the chicken orthologue of human IL-8, enhances healing by rapidly chemoattracting fibroblasts into the wound site and stimulating them to produce ECM molecules, leading to precocious development of granulation tissue. This acceleration of the repair process may have important application to healing of impaired wounds.